Paper29664013
β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.
Nsengimana J and 17 others. J Clin Invest, 2018. Cited by 83 papers, by iCite.
Cite this record
ConductScience Library. β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. Papers, record 29664013. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29664013
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| GTP Phosphohydrolases | Major topic |
| Melanoma | Major topic |
| Membrane Proteins | Major topic |
| Mutation | Major topic |
| Proto-Oncogene Proteins B-raf | Major topic |
| Skin Neoplasms | Major topic |
| Tumor Microenvironment | Major topic |
| beta Catenin | Major topic |
| Female | |
| Humans | |
| Male |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| MR/M019012/1 | Medical Research Council | United Kingdom | PubMed | |
| 19167 | Cancer Research UK | United Kingdom | PubMed | |
| 11963 | Cancer Research UK | United Kingdom | PubMed | |
| 10589 | Cancer Research UK | United Kingdom | PubMed | |
| MR/L01629X/1 | Medical Research Council | United Kingdom | PubMed | |
| MR/S00386X/1 | Medical Research Council | United Kingdom | PubMed | |
| G0802123 | Medical Research Council | United Kingdom | PubMed |
Source PubMed
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27660706 | A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. | J Immunother Cancer | 2016 | https://conductscience.org/library/papers/27660706 | PubMed |
| 2 | 25399551 | Improved overall survival in melanoma with combined dabrafenib and trametinib. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25399551 | PubMed |
| 3 | 24258985 | Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. | Methods Mol Biol | 2014 | https://conductscience.org/library/papers/24258985 | PubMed |
| 4 | 25403087 | 25-Hydroxyvitamin D2 /D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort. | Int J Cancer | 2015 | https://conductscience.org/library/papers/25403087 | PubMed |
| 5 | 2593166 | Model predicting survival in stage I melanoma based on tumor progression. | J Natl Cancer Inst | 1989 | https://conductscience.org/library/papers/2593166 | PubMed |
| 6 | 23424623 | Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. | PLoS One | 2013 | https://conductscience.org/library/papers/23424623 | PubMed |
| 7 | 27525433 | Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. | J Clin Invest | 2016 | https://conductscience.org/library/papers/27525433 | PubMed |
| 8 | 28650338 | IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. | J Clin Invest | 2017 | https://conductscience.org/library/papers/28650338 | PubMed |
| 9 | 27345472 | Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities. | J Invest Dermatol | 2016 | https://conductscience.org/library/papers/27345472 | PubMed |
| 10 | 25970248 | Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. | Nature | 2015 | https://conductscience.org/library/papers/25970248 | PubMed |
| 11 | 25446897 | Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. | Cancer Cell | 2014 | https://conductscience.org/library/papers/25446897 | PubMed |
| 12 | 23890060 | The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. | Immunity | 2013 | https://conductscience.org/library/papers/23890060 | PubMed |
| 13 | 24113773 | Inferring tumour purity and stromal and immune cell admixture from expression data. | Nat Commun | 2013 | https://conductscience.org/library/papers/24113773 | PubMed |
| 14 | 20705614 | Patterns of expression of DNA repair genes and relapse from melanoma. | Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20705614 | PubMed |
| 15 | 24894088 | VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. | Cancer Immunol Res | 2014 | https://conductscience.org/library/papers/24894088 | PubMed |
| 16 | 26091043 | Genomic Classification of Cutaneous Melanoma. | Cell | 2015 | https://conductscience.org/library/papers/26091043 | PubMed |
| 17 | 21779876 | Prognostic impact of B-cell density in cutaneous melanoma. | Cancer Immunol Immunother | 2011 | https://conductscience.org/library/papers/21779876 | PubMed |
| 18 | 26146664 | Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. | JAMA Oncol | 2015 | https://conductscience.org/library/papers/26146664 | PubMed |
| 19 | 26317168 | Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and advanced tumor stage in melanoma. | Melanoma Res | 2015 | https://conductscience.org/library/papers/26317168 | PubMed |
| 20 | 15534099 | X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. | Clin Cancer Res | 2004 | https://conductscience.org/library/papers/15534099 | PubMed |
Cited by71
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 83 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42716012 | Functional characterization of the 9q34.13 locus identifies RAPGEF1 as a candidate gene modulating risk for melanoma and nevi via RAS activation. | Am J Hum Genet | 2026 | https://conductscience.org/library/papers/42716012 | PubMed |
| 42120944 | Tumor Anti-Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment. | Cancer Med | 2026 | https://conductscience.org/library/papers/42120944 | PubMed |
| 42100918 | Functional characterization of the 9q34.13 locus identifies RAPGEF1 as modulating risk for melanoma and nevi via RAS activation. | bioRxiv | 2026 | https://conductscience.org/library/papers/42100918 | PubMed |
| 42056900 | Differentiation state affects PD-L1 expression in cutaneous melanoma: a systematic review. | Cell Mol Biol Lett | 2026 | https://conductscience.org/library/papers/42056900 | PubMed |
| 41855479 | LncRNA Dlx4os drives malignant transformation and phenotype switching in melanoma. | Epigenetics | 2026 | https://conductscience.org/library/papers/41855479 | PubMed |
| 41553603 | Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment : Author List. | Curr Treat Options Oncol | 2026 | https://conductscience.org/library/papers/41553603 | PubMed |
| 41542517 | Functional characterization of a multi-cancer risk locus on chromosome band 2q33.1 near CASP8. | bioRxiv | 2026 | https://conductscience.org/library/papers/41542517 | PubMed |
| 41002441 | Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies. | Cells | 2025 | https://conductscience.org/library/papers/41002441 | PubMed |
| 40913277 | LRP2 Expression in Melanoma Is Associated With a Transitory Cell State, Increased T Cell Infiltration, and Is Upregulated by IFNy Signaling. | Pigment Cell Melanoma Res | 2025 | https://conductscience.org/library/papers/40913277 | PubMed |
| 39786688 | The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma. | Eur J Epidemiol | 2025 | https://conductscience.org/library/papers/39786688 | PubMed |
| 39583094 | Development of mutated β-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC. | JHEP Rep | 2024 | https://conductscience.org/library/papers/39583094 | PubMed |
| 39509669 | DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. | JCO Precis Oncol | 2024 | https://conductscience.org/library/papers/39509669 | PubMed |
| 39098861 | Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy. | Nat Commun | 2024 | https://conductscience.org/library/papers/39098861 | PubMed |
| 38903502 | Dendritic cell subsets and implications for cancer immunotherapy. | Front Immunol | 2024 | https://conductscience.org/library/papers/38903502 | PubMed |
| 38341461 | A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC). | Prostate Cancer Prostatic Dis | 2025 | https://conductscience.org/library/papers/38341461 | PubMed |
| 37888209 | Crosstalk between Non-Coding RNAs and Wnt/β-Catenin Signaling in Head and Neck Cancer: Identification of Novel Biomarkers and Therapeutic Agents. | Noncoding RNA | 2023 | https://conductscience.org/library/papers/37888209 | PubMed |
| 37873189 | ARF6-dependent endocytic trafficking of the Interferon-γ receptor drives adaptive immune resistance in cancer. | bioRxiv | 2023 | https://conductscience.org/library/papers/37873189 | PubMed |
| 37586766 | Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/37586766 | PubMed |
| 37189643 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. | Biomedicines | 2023 | https://conductscience.org/library/papers/37189643 | PubMed |
| 36620565 | Frizzled receptors in melanomagenesis: From molecular interactions to target identification. | Front Oncol | 2022 | https://conductscience.org/library/papers/36620565 | PubMed |
Genes48
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29664013
GET https://conductscience.org/api/papers/v1/29664013/references?page=2